Replies to post #123915 on Bioelectronics Corp (BIEL)

[ssmmss]

I agree with you. But you took my words literally, I am not looking for another announcement, I am looking for pennyland. Price hasn't moved, it's a fraction of penny. We should be at $90M market cap.

Investors are not looking for another announcement or study results or all those fluffy PRs or another partnership, they are looking for exponential sales numbers, something this company failed to deliver in all the markets we have been operating in for years.

We failed miserably in the UK and the FDA approval ain't gonna do jack for us in the US. We don't have an issue with clearances, we have an issue with Marketing. This company should have been doing 10-20 million dollars per quarter for the past several years. If the British didn't buy it, the Americans won't either, if the Canadians didn't buy it, the Americans won't either.......and the list goes on and on and on.

We all know the product works and something is profoundly missing from this company.

A year has passed since the last clearance, what have we gained? Nothing, nada. As a matter of fact, take a look at the cost of good sold for Q2 2017, it was embarrassingly higher than any other Q even though the sales numbers were pretty much the same.

Trust me, all those bullets are not helping your bank account. If this company does not come up with some serious numbers for Q1 and Q2, then we are dead. I am talking about 5+ million dollars in sales in Q2 and hopefully a couple mil for Q1. Throw in there some Walmart and CVS hype and we will get to pennyland.

[lizanne1890]

Last night on CNN I saw a quick flash of an Ad for Innovate Biopharmaceuticals Inc.

[Gramps]

If I was running this company...

...and I was busting my hump like Team BIEL has in the last year to achieve the list below, I would be very encouraged that all of my efforts were not in vain, that I understood these efforts are not going to produce revenues YET but were the foundations...the seeds towards eventual success. Without them...no success. The listing below represents foundations towards success--no question. Remarkable achievements so far. Seeds...young trees in the making, and alot of them.

But if I were to hear of others complaining that there aren't any trees yet, that my efforts failed because they can't see them or don't believe they are there---I would either be discouraged or angry and want to tell them to just go away.

In the big picture, BIEL has just planted the seeds in the U.S. But they are in a position where they can--which was a HUGE hurdle. The market is there and we have permission to plant our seeds there. And on the horizon more fields available to us in the world of pain management. We have only just begun so I don't expect big revenues---yet. I'm continuing to wait and watch---seedlings will all start popping up this year. THAT for me as an investor will be progress. Eventually, there will be established trees everywhere. That is what is happening and yes, it will be worth the wait.

From srinsocal's post:

"Seriously, what have we done?"

"It has been a year since we last got clearance. What have we done? Seriously, what have we done?"

I am very excited about what BIEL has achieved in the last Year. While I would agree that it has not yet translated into increased sales, as far as we know from the last available Q3 Report, several of the key events have just hit in the last couple of months. The biggest event, NHS Approval, was made public last month but does not kick in until April.

Seriously, this is what we have done:

* Received FDA Clearance for two Indications

* Received FDA OTC Clearance

* Received UK National Health System Coverage for Chronic Pain

* Received US National Distribution through ANDA the US branch of TEVA distribution, 60,000 retail customers

* Hired Keith Nalepka, an experienced, aggressive VP of Sales with industry contacts

* Initiated and completed a 100 patient Back Pain Study, multi billion dollar market

* Meetings with FDA to finalize Full Body FDA Clearance Application

* Initiated Migraine Prevention Study, multi billion dollar market

* Initiated Menstrual Pain Study at Birmingham Women's Hospital, UK NHS Foundation Hospital, multi billion dollar market

* Signed Deal with CARE, 90 member Independent Pharmacy Group for Distribution and Education

* Deal with Mundi Pharma,Distribution in 9 Countries, Mundi is a global distribution network operating in 120 countries

* Deal with Performance Health Distribution, another global company specializing in rehab and sports medicine porducts

* Licensed ActiPatch to PharmEvo, another global company, for Asia sales under the 'Pain Gear' name

* Signed Deal with TESCO, the third largest retailer in the world